Skip to main content
Clinical Trials/ACTRN12624000720516
ACTRN12624000720516
Recruiting
未知

A Randomised Controlled Trial Evaluating an In-Person, Clinician-Facilitated and an Online, Guided Self-Help Program for University Students with Social Anxiety

Professor Elizabeth Rieger0 sites90 target enrollmentJune 12, 2024

Overview

Phase
未知
Intervention
Not specified
Conditions
Social Anxiety Disorder
Sponsor
Professor Elizabeth Rieger
Enrollment
90
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 12, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Professor Elizabeth Rieger

Eligibility Criteria

Inclusion Criteria

  • Must be diagnosed with Social Anxiety Disorder by a registered psychologist or provisional psychologist in the Psychology Clinic of the Australian National University.
  • Enrolled as a student at the Australian National University or the University of Canberra.

Exclusion Criteria

  • Current suicidal intent, psychotic illness, substance use disorder or severe depression. Exclusion criteria are assessed during initial screening in individual meetings with a registered psychologist or provisional psychologist in the Psychology Clinic of the Australian National University.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
This is a study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD)Subjects with moderately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2021-002869-18-BEAbbVie Deutschland GmbH & Co. KG265
Active, not recruiting
Phase 1
Clinical Trial to compare if seriously-ill adults with constipation due to narcotics have bowel movements sooner after injection with Methylnatrexone or placebo
EUCTR2007-000854-30-BESalix Pharmaceuticals Inc254
Active, not recruiting
Not Applicable
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 17.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2013-002343-29-GBRegeneron Pharmaceuticals, Inc.803
Active, not recruiting
Not Applicable
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease - E5555-G000-201Coronary Artery DiseaseMedDRA version: 8.1Level: PTClassification code 10011078
EUCTR2005-006029-94-BEEisai Limited720
Completed
Not Applicable
A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of JNJ-26070109abdominal pain and heartburn10017943
NL-OMON30044Janssen-Cilag82